307 related articles for article (PubMed ID: 36851792)
1. Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19.
Kim MI; Lee C
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851792
[TBL] [Abstract][Full Text] [Related]
2. Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2.
Schirtzinger EE; Kim Y; Davis AS
J Virol Methods; 2022 Jan; 299():114317. PubMed ID: 34634321
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of human coronavirus OC43 and SARS-COV-2 in children with respiratory tract infection during the COVID-19 pandemic.
Keshavarz Valian N; Pourakbari B; Asna Ashari K; Hosseinpour Sadeghi R; Mahmoudi S
J Med Virol; 2022 Apr; 94(4):1450-1456. PubMed ID: 34786736
[TBL] [Abstract][Full Text] [Related]
4. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
[TBL] [Abstract][Full Text] [Related]
5. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
6. Activation of STING Signaling Pathway Effectively Blocks Human Coronavirus Infection.
Liu W; Reyes HM; Yang JF; Li Y; Stewart KM; Basil MC; Lin SM; Katzen J; Morrisey EE; Weiss SR; You J
J Virol; 2021 May; 95(12):. PubMed ID: 33789998
[TBL] [Abstract][Full Text] [Related]
7. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
8. An overview on the seven pathogenic human coronaviruses.
Kesheh MM; Hosseini P; Soltani S; Zandi M
Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
[TBL] [Abstract][Full Text] [Related]
9. Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
Pasquero S; Gugliesi F; Griffante G; Dell'Oste V; Biolatti M; Albano C; Bajetto G; Delbue S; Signorini L; Dolci M; Landolfo S; De Andrea M
Antiviral Res; 2022 Apr; 200():105278. PubMed ID: 35288208
[TBL] [Abstract][Full Text] [Related]
10. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
[TBL] [Abstract][Full Text] [Related]
11. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study.
Townsend JP; Hassler HB; Wang Z; Miura S; Singh J; Kumar S; Ruddle NH; Galvani AP; Dornburg A
Lancet Microbe; 2021 Dec; 2(12):e666-e675. PubMed ID: 34632431
[TBL] [Abstract][Full Text] [Related]
12. Effective inhibition of HCoV-OC43 and SARS-CoV-2 by phytochemicals in vitro and in vivo.
Ojha D; Jessop F; Bosio CM; Peterson KE
Int J Antimicrob Agents; 2023 Sep; 62(3):106893. PubMed ID: 37339711
[TBL] [Abstract][Full Text] [Related]
13. Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.
Chen Y; Wang X; Shi H; Zou P
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632604
[TBL] [Abstract][Full Text] [Related]
14. Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the hologic panther fusion.
Cordes AK; Rehrauer WM; Accola MA; Wölk B; Hilfrich B; Heim A
J Med Virol; 2021 Jul; 93(7):4438-4445. PubMed ID: 33350484
[TBL] [Abstract][Full Text] [Related]
15. The Stability of Model Human Coronaviruses on Textiles in the Environment and during Health Care Laundering.
Owen L; Shivkumar M; Laird K
mSphere; 2021 Apr; 6(2):. PubMed ID: 33910996
[TBL] [Abstract][Full Text] [Related]
16. Optimizing human coronavirus OC43 growth and titration.
Savoie C; Lippé R
PeerJ; 2022; 10():e13721. PubMed ID: 35833016
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Interaction Between Spike Protein and Nucleocapsid Protein for Suppression and Detection of Human Coronavirus OC43.
Kim J; Kim M; Kim D; Park S; Kang M; Baek K; Choi JK; Maharjan S; Akauliya M; Lee Y; Kwon HJ
Front Immunol; 2022; 13():835333. PubMed ID: 35359936
[TBL] [Abstract][Full Text] [Related]
18. Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4).
Kaur R; Tada T; Landau NR
mBio; 2023 Aug; 14(4):e0109023. PubMed ID: 37382452
[TBL] [Abstract][Full Text] [Related]
19. Cytopathic Effect Assay and Plaque Assay to Evaluate
Hu Y; Ma C; Wang J
Bio Protoc; 2022 Feb; 12(3):e4314. PubMed ID: 35284599
[TBL] [Abstract][Full Text] [Related]
20. Roles of Sialyl Glycans in HCoV-OC43, HCoV-HKU1, MERS-CoV and SARS-CoV-2 Infections.
Sriwilaijaroen N; Suzuki Y
Methods Mol Biol; 2022; 2556():243-271. PubMed ID: 36175638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
